Achilles Therapeutics PLC (ACHL)
1.07
0.00 (0.00%)
USD |
NASDAQ |
Nov 21, 16:00
1.07
0.00 (0.00%)
After-Hours: 20:00
Achilles Therapeutics Enterprise Value: -42.09M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -42.09M |
| November 20, 2024 | -42.09M |
| November 19, 2024 | -42.91M |
| November 18, 2024 | -42.91M |
| November 15, 2024 | -42.91M |
| November 14, 2024 | -42.09M |
| November 13, 2024 | -44.14M |
| November 12, 2024 | -44.55M |
| November 11, 2024 | -43.32M |
| November 08, 2024 | -42.91M |
| November 07, 2024 | -43.12M |
| November 06, 2024 | -43.12M |
| November 05, 2024 | -43.53M |
| November 04, 2024 | -43.94M |
| November 01, 2024 | -44.14M |
| October 31, 2024 | -44.96M |
| October 30, 2024 | -44.14M |
| October 29, 2024 | -45.17M |
| October 28, 2024 | -45.38M |
| October 25, 2024 | -45.79M |
| October 24, 2024 | -45.78M |
| October 23, 2024 | -44.97M |
| October 22, 2024 | -45.17M |
| October 21, 2024 | -45.29M |
| October 18, 2024 | -44.96M |
| Date | Value |
|---|---|
| October 17, 2024 | -45.38M |
| October 16, 2024 | -45.38M |
| October 15, 2024 | -45.58M |
| October 14, 2024 | -45.58M |
| October 11, 2024 | -45.43M |
| October 10, 2024 | -45.91M |
| October 09, 2024 | -44.96M |
| October 08, 2024 | -44.14M |
| October 07, 2024 | -44.55M |
| October 04, 2024 | -43.89M |
| October 03, 2024 | -44.14M |
| October 02, 2024 | -45.36M |
| October 01, 2024 | -44.96M |
| September 30, 2024 | -44.14M |
| September 27, 2024 | -53.41M |
| September 26, 2024 | -54.76M |
| September 25, 2024 | -55.87M |
| September 24, 2024 | -56.08M |
| September 23, 2024 | -55.03M |
| September 20, 2024 | -52.38M |
| September 19, 2024 | -56.49M |
| September 18, 2024 | -65.94M |
| September 17, 2024 | -66.02M |
| September 16, 2024 | -66.10M |
| September 13, 2024 | -65.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-157.05M
Minimum
May 09 2022
566.38M
Maximum
Apr 06 2021
-56.60M
Average
-93.74M
Median
Feb 07 2024
Enterprise Value Benchmarks
| Autolus Therapeutics PLC | 98.72M |
| Biodexa Pharmaceuticals PLC | -3.355M |
| Centessa Pharmaceuticals PLC | 1.956B |
| Adaptimmune Therapeutics PLC | 26.67M |
| Verona Pharma PLC | 2.882B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.60M |
| Total Expenses (Quarterly) | 20.42M |
| EPS Diluted (Quarterly) | -0.48 |
| Earnings Yield | -154.2% |